March 29, 2019 10:46 AM EDT

Rare disease gene therapy gains Prime status; FDA approves first drug for inflammatory arthritis nr-axSpA

John Carroll

Editor & Founder

→ Pittsburgh-based Krystal Biotech $KRYS has won the EMA’s Prime status for its gene therapy to treat dystrophic epidermolysis bullosa. The company says regulators …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Rare disease gene therapy gains Prime status; FDA approves first drug for inflammatory arthritis nr-axSpA

John Carroll

Editor & Founder

Sign up to read this article for free.

The Endpoints 2024 winners and losers list: Who was up and who was down in biopharma

Sofinnova outlines $550M fund after IPOs and M&A deals

Updated: Novo’s 23% weight loss with CagriSema falls short of high expectations, new trial planned

Accelerated approval brings Pfizer's BRAF inhibitor to first-line patients

FDA approves Humacyte’s lab-grown blood vessels in milestone for regenerative medicine

GSK's Zejula-Jemperli combo in ovarian cancer hits primary endpoint, misses on overall survival

Rare dis­ease gene ther­a­py gains Prime sta­tus; FDA ap­proves first drug for in­flam­ma­to­ry arthri­tis nr-axS­pA

John Carroll

Editor & Founder

Sign up to read this article for free.

more like this

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

GSK's Ze­ju­la-Jem­per­li com­bo in ovar­i­an can­cer hits pri­ma­ry end­point, miss­es on over­all sur­vival

Rare disease gene therapy gains Prime status; FDA approves first drug for inflammatory arthritis nr-axSpA

The Endpoints 2024 winners and losers list: Who was up and who was down in biopharma

Sofinnova outlines $550M fund after IPOs and M&A deals

Updated: Novo’s 23% weight loss with CagriSema falls short of high expectations, new trial planned

Accelerated approval brings Pfizer's BRAF inhibitor to first-line patients

FDA approves Humacyte’s lab-grown blood vessels in milestone for regenerative medicine

GSK's Zejula-Jemperli combo in ovarian cancer hits primary endpoint, misses on overall survival